- Immunotherapy using LEAPS peptide technology may be able to reduce COVID-19 viral load and tissue damage resulting from infection in the lungs.
- Studies conducted in collaboration with NIAID showed LEAPS peptides reduced morbidity and mortality in mice with another respiratory virus, pandemic influenza (H1N1).
VIENNA, VA, USA I March 9, 2020 I CEL-SCI Corporation (NYSE American: CVM) announces that it is developing an immunotherapy with the potential to treat the COVID-19 coronavirus using its patented LEAPS peptide technology. The LEAPS peptides will utilize conserved regions of coronavirus proteins to stimulate protective cell mediated T cell responses and reduce viral load. The LEAPS peptide technology can be used to construct immunotherapeutic peptides that exhibit both antiviral and anti-inflammatory properties. Consequently, these products not only target the virus infection against which they are directed, but also elicit the appropriate protective response(s) against it. Read more.